Panelists discuss how evolving clinical guidelines for intensive low-density lipoprotein cholesterol (LDL-C)–lowering therapies have shaped personalized treatment approaches through risk stratification, with different targets for primary vs secondary prevention and consideration of genetic factors when determining appropriate statin intensity.
Panelists discuss how cardiology practice has evolved toward more aggressive low-density lipoprotein cholesterol (LDL-C)–lowering strategies across specialties, with current guidelines generally recommending targets below 70 mg/dL for high-risk patients and even lower thresholds (below 55 mg/dL) for very high-risk individuals, though these targets require personalization based on age, comorbidities such as diabetes and hypertension, and other cardiovascular risk factors.
Expert provides a comprehensive overview of drug diversion prevention in pharmacy settings.
Christine Barrett, PharmD, BCOP, shares insights, challenges, and advice for oncology pharmacists navigating neoadjuvant therapy.
Jessica Davis, PharmD, BCOP highlights the role of pharmacy technicians in ambulatory oncology clinic settings.
Lauren Dietz, PharmD, highlighted the role of oncology pharmacists in guiding prophylaxis decisions to optimize transplant outcomes.
Julia Ziegengeist, PharmD, BCOP offers insights for pharmacists navigating adjuvant and neoadjuvant treatment of breast cancer.
Amir Ali, PharmD, BCOP, and Allison Hsieh, PharmD share insights from their presentation about cytokine release syndrome, ICANS, and CAR T-cell therapy.
Alexandra Wolff, PharmD, BCOP, FHOPA, was awarded a fellow of HOPA at the 2025 annual meeting.
Panelists discuss how there have been many new agents being studied and released at the current time and how the development of these agents is moving at a rapid pace. The adverse effect profiles of newer antibody-drug conjugates create a greater opportunity for pharmacists to be involved in toxicity management.
Mya Tran, PharmD, BCOP, offers insights for navigating the complex treatment landscape for non-small cell lung cancer.
Michael Arnold, PharmD, discussed the role of oncology pharmacists in enhancing biomarker testing for patients with metastatic colorectal cancer.
Nilufer Ertekin-Taner contrasts current one-size-fits-all Alzheimer disease treatments with the promise of precision medicine and emphasizes the vital role of collaborative, multidisciplinary care.
Erin Harrell, PharmD, offers insights about managing peripheral neuropathy in patients receiving bortezomib.
The HERCULES trial demonstrates tolebrutinib's potential to slow disability progression in non-relapsing secondary progressive multiple sclerosis, offering a new treatment option for patients with limited therapeutic choices.
Kara Melmed, MD, emphasizes the critical importance of rapid, team-based intervention for intracerebral hemorrhage (ICH) patients, with pharmacists playing a key role in blood pressure management.
Pharmacists are essential navigators in the complex landscape of gene therapy.
Kayla Johnson, PharmD, BCPS, BCPP, highlights how integrating pharmacists into neurology clinics drives significant cost savings, high intervention acceptance rates, and improved care coordination.
Enriqueta Felip, MD, PhD, discussed the benefits of subcutaneous pembrolizumab for patients with metastatic non–small cell lung cancer.
Stephanie Miller, PhD discusses how artificial intelligence can revolutionize medical research by assisting in drug development and potentially providing more targeted treatments across various diseases.
Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, offers insights for oncology pharmacists treating patients with metastatic esophageal squamous cell carcinoma.
Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discusses a case study of a patient with metastatic esophageal squamous cell carcinoma.
Glucagon-like peptide-1 (GLP-1) analogs demonstrate potential to address multiple pathological processes in Alzheimer disease, with promising early research suggesting cognitive improvements and potential for future treatment.
Andrew Charles, MD, outlines why calcitonin-gene-related peptide (CGRP) antagonists are increasingly favored as first-line migraine treatments and how pharmacists play a key role in patient education and support.
A study led by Kayla Johnson, PharmD, BCPS, BCPP found that integrating specialty pharmacists into non-multiple sclerosis (MS) neurology clinics led to significantly enhanced patient care and treatment outcomes.
Beth A. Malow, MD, MS, FAAN, said that pharmacists and health care professionals are at the frontlines of collaborating and raising awareness of climate change’s impacts.
Malow also emphasized the importance of staying educated on the potential neurological risks that may occur as a result of climate change.
Nilufer Ertekin-Taner outlines how embracing the biological complexity of neurodegenerative diseases can guide the development of precision therapies akin to those used in oncology.
Panelists discuss how optimizing antibody-drug conjugate (ADC) therapy in patients with metastatic breast cancer (mBC) requires interdisciplinary care, including oncologists, pharmacists, and nurses. Adherence barriers such as cost, access, and insurance are addressed via financial and social support.
Panelists discuss how health care professionals use clear, tailored communication to explain antibody-drug conjugate (ADC) risks, benefits, and regimens. They provide education, address concerns, and ensure adherence through counseling and shared decision-making.
